Product Pathways - Cell Cycle / Checkpoint
Cyclin D3 (DCS22) Mouse mAb #2936
PhosphoSitePlus® protein, site, and accession data: CCND3
| Applications | Reactivity | Sensitivity | MW (kDa) | Isotype |
|---|---|---|---|---|
| W IHC-P | H M R | Endogenous | 31 | Mouse IgG1 |
Applications Key:
W=Western Blotting
IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:
H=Human
M=Mouse
R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Protocols
- 2936:
- IHC / Paraffin, Western Blotting
Specificity / Sensitivity
Cyclin D3 (DCS22) Mouse mAb detects endogenous levels of total cyclin D3 protein. The antibody does not cross-react with cyclin D1 or cyclin D2.
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant human cyclin D3 corresponding to residues 241-260.
Western Blotting
Western blot analysis of extracts from SK-N-MC, C6 and IMCD3 cells, using Cyclin D3 (DCS22) Mouse mAb.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Cyclin D3 (DCS22) Mouse mAb.
IHC-P (paraffin)
Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using Cyclin D3 (DCS22) Mouse mAb.
Background
Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins (1). The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase (2). The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression (3). Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation (4).
Although the D-type cyclins are not fully redundant, cyclin D3, like D1, plays a prominent role in differentiation and proliferation, which correlates with higher expression levels of cyclin D3 in various cancers (5).
- Hirai, H. et al. (1995) Mol. Cell. Biol. 15, 2672-2681.
- Sherr, C.J. (1996) Science 274, 1672-1677.
- Lukas, J. et al. (1996) Mol. Cell. Biol. 16, 6917-6925.
- Diehl, J.A. et al. (1997) Genes Dev. 11, 957-972.
- Bartkova, J. et al. (1998) Oncogene 17, 1027-37.
Application References
- Bartkova, J. et al. (1998) Oncogene 17, 1027-37. Applications: IC-IF Western Blotting
- Bartkova, J. et al. (2001) Aberrant expression of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Gastroenterology 120, 1680-1688. Applications: IHC-P (paraffin)
- Bartkova, J. et al. (1996) Abundance and subcellular localization of cyclin D3 in human tumours. Int. J. Cancer 65, 323-327. Applications: IC-IF IHC-P (paraffin) Western Blotting
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 2926 Cyclin D1 (DCS6) Mouse mAb
- 7076 Anti-mouse IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
- 8125 SignalStain® Boost IHC Detection Reagent (HRP, Mouse)
For Research Use Only. Not For Use In Diagnostic Procedures.
